Bioenergetics of Metformin Action and Aging

二甲双胍作用与衰老的生物能学

基本信息

  • 批准号:
    10665658
  • 负责人:
  • 金额:
    $ 36.7万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-15 至 2025-06-30
  • 项目状态:
    未结题

项目摘要

Abstract. Metformin has been used as a medication for the treatment of diabetes for approximately 70 years. Besides diabetes, biguanides are associated with a number of other beneficial effects prevention/treatment of cancer, cardiovascular disease, neurodegenerative disease, and weight loss. Metformin has also been shown to increase health span and prolong life span. Despite these wide-ranging pleotropic effects, the primary molecular mechanism of action is still unresolved. Aging is arguably the single greatest risk factor for most diseases. This application is based on the premise that deciphering metformin's molecular mechanism of action will provide a better understanding of how the aging process and aging-related diseases may be more effectively targeted. Based on extensive preliminary data and fundamental, yet often underappreciated, thermodynamic and bioenergetic principles, the central hypothesis of this project is that a mild reduction in mitochondrial bioenergetic efficiency is the primary molecular mechanism by which metformin, and other organic cations, extend health span and/or lifespan. It is further hypothesized that the efficacy of metformin on health span depends on the chronic metabolic state – beneficial under caloric surplus but detrimental under caloric deficit conditions. State-of-the-art in vivo and in vitro approaches will be used: to establish the interaction of aging and metformin (and other organic cations) on mitochondrial bioenergetic efficiency in mitochondria isolated from heart, skeletal muscle, liver, kidney, intestine and brain from 3, 12, and 24 month old Fischer 344 rats (Aim 1); to establish the acute interaction of metformin and metabolic state (low or high fat diet, fed or fasted) in vivo in 12 month old rats (Aim 2); and to determine the context specific impact of metformin on health span and lifespan in male and female rats. The outcomes of this project are expected to demonstrate that metformin, similar to other organic cations, dose-dependently decreases mitochondrial bioenergetic efficiency, revealing a primary mechanism that can account for the numerous downstream cellular and physiological effects, including protection from aging-related diseases.
抽象的。 二甲双胍被用作治疗糖尿病的药物已有近70年的历史 好几年了。除糖尿病外,双胍类化合物还具有许多其他有益作用。 预防/治疗癌症、心血管疾病、神经退行性疾病和体重 损失。二甲双胍也被证明可以增加健康寿命和延长寿命。尽管 这些广泛的多效性效应,主要的分子作用机制仍然是 悬而未决。可以说,衰老是大多数疾病的最大风险因素。此应用程序 是基于这样一个前提,破译二甲双胍的分子作用机制将 更好地了解衰老过程和与衰老相关的疾病 更有效的针对性。基于广泛的初步数据和基本数据,但通常 被低估的热力学和生物能量学原理,这一中心假设 项目是线粒体生物能效率的轻微下降是主要分子 二甲双胍和其他有机阳离子延长健康寿命和/或寿命的机制。 进一步假设,二甲双胍对健康持续时间的疗效取决于慢性 代谢状态-在卡路里过剩的情况下有益,但在卡路里不足的情况下有害。 将使用最先进的体内和体外方法:建立衰老的相互作用 和二甲双胍(和其他有机阳离子)对线粒体生物能效率的影响 从心脏、骨骼肌、肝、肾、肠和脑中分离出线粒体3,12, 和24月龄Fischer 344只大鼠(目标1);建立二甲双胍与Fischer 344大鼠的急性相互作用 12月龄大鼠体内代谢状态(低或高脂肪饮食,喂养或禁食)(目标2); 确定二甲双胍对男性和女性健康寿命和寿命的具体影响 雌性老鼠。该项目的结果预计将证明二甲双胍,类似于 其他有机阳离子会剂量依赖性地降低线粒体的生物能量效率, 揭示了一种主要机制,可以解释众多下游细胞和 生理效应,包括对衰老相关疾病的保护。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

P Darrell Neufer其他文献

P Darrell Neufer的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('P Darrell Neufer', 18)}}的其他基金

Bioenergetics of Metformin Action and Aging
二甲双胍作用与衰老的生物能学
  • 批准号:
    10432123
  • 财政年份:
    2020
  • 资助金额:
    $ 36.7万
  • 项目类别:
Bioenergetics of Metformin Action and Aging
二甲双胍作用与衰老的生物能学
  • 批准号:
    10087213
  • 财政年份:
    2020
  • 资助金额:
    $ 36.7万
  • 项目类别:
Bioenergetics of Metformin Action and Aging
二甲双胍作用与衰老的生物能学
  • 批准号:
    10263356
  • 财政年份:
    2020
  • 资助金额:
    $ 36.7万
  • 项目类别:
Statins: Mitochondrial Function and Aerobic Capacity
他汀类药物:线粒体功能和有氧能力
  • 批准号:
    9260468
  • 财政年份:
    2017
  • 资助金额:
    $ 36.7万
  • 项目类别:
Statins: Mitochondrial Function and Aerobic Capacity
他汀类药物:线粒体功能和有氧能力
  • 批准号:
    10188421
  • 财政年份:
    2017
  • 资助金额:
    $ 36.7万
  • 项目类别:
Impact of organic cations on mitochondrial energetic driving forces and metabolic efficiency
有机阳离子对线粒体能量驱动力和代谢效率的影响
  • 批准号:
    9169876
  • 财政年份:
    2016
  • 资助金额:
    $ 36.7万
  • 项目类别:
Impact of organic cations on mitochondrial energetic driving forces and metabolic efficiency
有机阳离子对线粒体能量驱动力和代谢效率的影响
  • 批准号:
    9306069
  • 财政年份:
    2016
  • 资助金额:
    $ 36.7万
  • 项目类别:
Redox Biology and Muscle Insulin Sensitivity
氧化还原生物学和肌肉胰岛素敏感性
  • 批准号:
    8400114
  • 财政年份:
    2012
  • 资助金额:
    $ 36.7万
  • 项目类别:
Redox Biology and Muscle Insulin Sensitivity
氧化还原生物学和肌肉胰岛素敏感性
  • 批准号:
    8511626
  • 财政年份:
    2012
  • 资助金额:
    $ 36.7万
  • 项目类别:
Redox Biology and Muscle Insulin Sensitivity
氧化还原生物学和肌肉胰岛素敏感性
  • 批准号:
    8891410
  • 财政年份:
    2012
  • 资助金额:
    $ 36.7万
  • 项目类别:

相似海外基金

Understanding age at first autism health claim and acute health service use in girls and women relative to boys and men
了解女孩和女性相对于男孩和男性的首次自闭症健康声明和紧急医疗服务使用情况
  • 批准号:
    419977
  • 财政年份:
    2020
  • 资助金额:
    $ 36.7万
  • 项目类别:
    Operating Grants
Study of pathogenic mechanism of age-dependent chromosome translocation in adult acute lymphoblastic leukemia
成人急性淋巴细胞白血病年龄依赖性染色体易位发病机制研究
  • 批准号:
    18K16103
  • 财政年份:
    2018
  • 资助金额:
    $ 36.7万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Proposal of a model plan for a high-activity operating department in an acute care hospital based on long-term PDCA in the age of minimally invasive treatment
微创治疗时代基于长期PDCA的急症医院高活动手术科室模型方案提出
  • 批准号:
    18K04486
  • 财政年份:
    2018
  • 资助金额:
    $ 36.7万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
ISCHAEMIC ACUTE RENAL FAILURE AND AGE: MODULATION BY ANTI-INFLAMMATORY EMBRYONIC STEM CELL-DERIVED MACROPHAGES
缺血性急性肾衰竭和年龄:抗炎胚胎干细胞源性巨噬细胞的调节
  • 批准号:
    G0801235/1
  • 财政年份:
    2009
  • 资助金额:
    $ 36.7万
  • 项目类别:
    Research Grant
AGE-RELATED DIFFERENCES IN ENERGY EXPENDITURE IN RESPONSE TO ACUTE EXERCISE
剧烈运动时的能量消耗与年龄相关的差异
  • 批准号:
    7951393
  • 财政年份:
    2009
  • 资助金额:
    $ 36.7万
  • 项目类别:
Age factors, mutations, and chemical suppressors of acute myelogenous leukemia
急性髓性白血病的年龄因素、突变和化学抑制剂
  • 批准号:
    8306217
  • 财政年份:
    2008
  • 资助金额:
    $ 36.7万
  • 项目类别:
Age-related differences in the acute thermoregulatory responses to cold
对寒冷的急性体温调节反应与年龄相关的差异
  • 批准号:
    347633-2008
  • 财政年份:
    2008
  • 资助金额:
    $ 36.7万
  • 项目类别:
    Postgraduate Scholarships - Master's
Age factors, mutations, and chemical suppressors of acute myelogenous leukemia
急性髓性白血病的年龄因素、突变和化学抑制剂
  • 批准号:
    7530462
  • 财政年份:
    2008
  • 资助金额:
    $ 36.7万
  • 项目类别:
Acute and chronic GPCR Medicated Cardioprotection: Roles of receptor Cross-Talk, Cellular signaling, and effects of Age
急性和慢性 GPCR 药物心脏保护:受体串扰的作用、细胞信号传导以及年龄的影响
  • 批准号:
    nhmrc : 428251
  • 财政年份:
    2008
  • 资助金额:
    $ 36.7万
  • 项目类别:
    Career Development Fellowships
Age factors, mutations, and chemical suppressors of acute myelogenous leukemia
急性髓性白血病的年龄因素、突变和化学抑制剂
  • 批准号:
    8134266
  • 财政年份:
    2008
  • 资助金额:
    $ 36.7万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了